Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 176

1.

Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.

Grinsztejn B, Hoagland B, Moreira RI, Kallas EG, Madruga JV, Goulart S, Leite IC, Freitas L, Martins LMS, Torres TS, Vasconcelos R, De Boni RB, Anderson PL, Liu A, Luz PM, Veloso VG; PrEP Brasil Study Team.

Lancet HIV. 2018 Mar;5(3):e136-e145. doi: 10.1016/S2352-3018(18)30008-0. Epub 2018 Feb 18.

PMID:
29467098
2.

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH.

Clin Infect Dis. 2018 Feb 6. doi: 10.1093/cid/cix1086. [Epub ahead of print]

PMID:
29420695
3.

Metabolic Effects of Pre-Exposure Prophylaxis with Co-Formulated Tenofovir Disoproxal Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Feb 3. doi: 10.1093/cid/ciy083. [Epub ahead of print]

PMID:
29415175
4.

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial.

Baxi SM, Vittinghoff E, Bacchetti P, Huang Y, Chillag K, Wiegand R, Anderson PL, Grant R, Greenblatt RM, Buchbinder S, Gandhi M, Liu AY.

PLoS One. 2018 Jan 9;13(1):e0190118. doi: 10.1371/journal.pone.0190118. eCollection 2018.

5.

Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.

Seifert SM, Castillo-Mancilla JR, Erlandson K, Morrow M, Gandhi M, Kuncze K, Horng H, Zheng JH, Bushman LR, Kiser JJ, MaWhinney S, Anderson PL.

J Acquir Immune Defic Syndr. 2018 Mar 1;77(3):295-298. doi: 10.1097/QAI.0000000000001596.

PMID:
29189417
6.

Continuum Reconfigurable Parallel Robots for Surgery: Shape Sensing and State Estimation with Uncertainty.

Anderson PL, Mahoney AW, Webster RJ 3rd.

IEEE Robot Autom Lett. 2017 Jul;2(3):1617-1624. doi: 10.1109/LRA.2017.2678606. Epub 2017 Mar 6.

PMID:
29159291
7.

Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.

Markowitz M, Grossman H, Anderson PL, Grant R, Gandhi M, Horng H, Mohri H.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):e104-e106. doi: 10.1097/QAI.0000000000001534. No abstract available.

PMID:
29076941
8.

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.

Anderson PL, Liu AY, Castillo-Mancilla JR, Gardner EM, Seifert SM, McHugh C, Wagner T, Campbell K, Morrow M, Ibrahim M, Buchbinder S, Bushman LR, Kiser JJ, MaWhinney S.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01710-17. doi: 10.1128/AAC.01710-17. Print 2018 Jan.

PMID:
29038282
9.

Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.

Koss CA, Hosek SG, Bacchetti P, Anderson PL, Liu AY, Horng H, Benet LZ, Kuncze K, Louie A, Saberi P, Wilson CM, Gandhi M.

Clin Infect Dis. 2018 Jan 6;66(2):213-219. doi: 10.1093/cid/cix755.

PMID:
29020194
10.

Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.

Tang EC, Vittinghoff E, Anderson PL, Cohen SE, Doblecki-Lewis S, Bacon O, Coleman ME, Buchbinder SP, Chege W, Kolber MA, Elion R, Shlipak M, Liu AY.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198. doi: 10.1097/QAI.0000000000001566.

PMID:
28991887
11.

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team.

Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3.

PMID:
28986029
12.

Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.

Hoornenborg E, Prins M, Achterbergh RCA, Woittiez LR, Cornelissen M, Jurriaans S, Kootstra NA, Anderson PL, Reiss P, de Vries HJC, Prins JM, de Bree GJ; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Consortium (H-TEAM).

Lancet HIV. 2017 Nov;4(11):e522-e528. doi: 10.1016/S2352-3018(17)30132-7. Epub 2017 Sep 14.

PMID:
28919303
13.

Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.

Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR.

J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):501-511. doi: 10.1097/QAI.0000000000001538.

PMID:
28902074
14.

Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.

Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, Horng H, Louie A, Kuncze K, Koss CA, Anderson PL, Buchbinder S, Liu A.

AIDS. 2017 Oct 23;31(16):2245-2251. doi: 10.1097/QAD.0000000000001615.

PMID:
28832411
15.

Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.

Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E; VicPrEP Study Team.

AIDS. 2017 Jul 31;31(12):1709-1714. doi: 10.1097/QAD.0000000000001519.

PMID:
28700394
16.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

PMID:
28639995
17.

High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.

Hoagland B, Moreira RI, De Boni RB, Kallas EG, Madruga JV, Vasconcelos R, Goulart S, Torres TS, Marins LMS, Anderson PL, Luz PM, Costa Leite ID, Liu AY, Veloso VG, Grinsztejn B; PrEP Brasil Study TeamClinical Trial Number 01989611.

J Int AIDS Soc. 2017 Apr 6;20(1):21472. doi: 10.7448/IAS.20.1.21472.

18.

Inflammation and pharmacokinetics: potential implications for HIV-infection.

Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL.

Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):641-650. doi: 10.1080/17425255.2017.1311323. Epub 2017 Apr 3. Review.

PMID:
28335648
19.

Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.

Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH; HPTN 067/ADAPT Study Team.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279. doi: 10.1097/QAI.0000000000001374.

PMID:
28328548
20.

Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Knox DC, Anderson PL, Harrigan PR, Tan DH.

N Engl J Med. 2017 Feb 2;376(5):501-502. doi: 10.1056/NEJMc1611639. No abstract available.

21.

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.

Fonsart J, Saragosti S, Taouk M, Peytavin G, Bushman L, Charreau I, Hance A, Goldwirt L, Morel S, Mammano F, Loze B, Capitant C, Clavel F, Mahjoub N, Meyer L, Anderson PL, Delaugerre C, Molina JM.

J Antimicrob Chemother. 2017 Feb;72(2):478-485. doi: 10.1093/jac/dkw412. Epub 2016 Sep 28.

PMID:
28073964
22.

Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.

Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Liu N, Wilson CM, Hazra R, Hosek SG, Anderson PL, Seifert SM, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions 117 study team.

Clin Infect Dis. 2017 Feb 1;64(3):317-325. doi: 10.1093/cid/ciw765. Epub 2016 Nov 15.

PMID:
28013265
23.

Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.

Chen X, Seifert SM, Castillo-Mancilla JR, Bushman LR, Zheng JH, Kiser JJ, MaWhinney S, Anderson PL.

PLoS One. 2016 Nov 10;11(11):e0165505. doi: 10.1371/journal.pone.0165505. eCollection 2016.

24.

A Case Series on the Effects of Kripalu Yoga for Generalized Anxiety Disorder.

Morgan JR, Sullivan M, Masuda A, Tully E, Cohen LL, Anderson PL.

Int J Yoga Therap. 2016 Jan;26(1):9-19.

PMID:
27797661
25.

Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.

Castillo-Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr, Gardner EM, Macatangay BJ, Breen EC, Jacobson LP, Anderson PL, Wada NI.

Clin Infect Dis. 2016 Dec 15;63(12):1661-1667. Epub 2016 Sep 22.

26.

A LC-MS/MS Method for Quantifying Adenosine, Guanosine and Inosine Nucleotides in Human Cells.

Jimmerson LC, Bushman LR, Ray ML, Anderson PL, Kiser JJ.

Pharm Res. 2017 Jan;34(1):73-83. doi: 10.1007/s11095-016-2040-z. Epub 2016 Sep 15.

27.

Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.

Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov.

28.

Pharmacology supports on-demand PrEP.

Glidden DV, Anderson PL, Grant RM.

Lancet HIV. 2016 Sep;3(9):e405-e406. doi: 10.1016/S2352-3018(16)30114-X. No abstract available.

29.

Development and validation of an LC-MS/MS quantitative method for endogenous deoxynucleoside triphosphates in cellular lysate.

Chen X, McAllister KJ, Klein B, Bushman LR, Anderson PL.

Biomed Chromatogr. 2017 Mar;31(3). doi: 10.1002/bmc.3820. Epub 2016 Sep 21.

30.

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Seifert SM, Chen X, Meditz AL, Castillo-Mancilla JR, Gardner EM, Predhomme JA, Clayton C, Austin G, Palmer BE, Zheng JH, Klein B, Kerr BJ, Guida LA, Rower C, Rower JE, Kiser JJ, Bushman LR, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):981-991. Epub 2016 Sep 19.

31.

Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.

Anderson PL, Reirden D, Castillo-Mancilla J.

J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S230-4. doi: 10.1097/QAI.0000000000001105. Review.

32.

A Case Series on the Effects of Kripalu Yoga for Generalized Anxiety Disorder.

Morgan JR, Sullivan M, Masuda A, Tully E, Cohen LL, Anderson PL.

Int J Yoga Therap. 2016 Jul 14. doi: 10.17761/1531-2054.0.0.000. [Epub ahead of print]

PMID:
27415154
33.

Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.

Chen X, Castillo-Mancilla JR, Seifert SM, McAllister KB, Zheng JH, Bushman LR, MaWhinney S, Anderson PL.

Antimicrob Agents Chemother. 2016 Aug 22;60(9):5387-92. doi: 10.1128/AAC.01019-16. Print 2016 Sep.

34.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL.

J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17.

35.

Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.

Zheng JH, Rower C, McAllister K, Castillo-Mancilla J, Klein B, Meditz A, Guida LA, Kiser JJ, Bushman LR, Anderson PL.

J Pharm Biomed Anal. 2016 Apr 15;122:16-20. doi: 10.1016/j.jpba.2016.01.038. Epub 2016 Jan 21.

36.

Robot-like dexterity without computers and motors: a review of hand-held laparoscopic instruments with wrist-like tip articulation.

Anderson PL, Lathrop RA, Webster RJ III.

Expert Rev Med Devices. 2016 Jul;13(7):661-72. doi: 10.1586/17434440.2016.1146585. Review.

PMID:
26808896
37.

Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.

Wong TC, Lan A, Kiser JJ, Anderson PL, Patel K, Tillman H, Naggie S.

Hepatology. 2016 Sep;64(3):999-1000. doi: 10.1002/hep.28461. Epub 2016 Mar 18. No abstract available.

38.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

39.

Don't ask, don't tell: a systematic review of the extent to which participant characteristics are reported in social anxiety treatment studies.

Johnson SB, Anderson PL.

Anxiety Stress Coping. 2016 Nov;29(6):589-605. doi: 10.1080/10615806.2016.1138289. Epub 2016 Feb 18. Review.

PMID:
26728858
40.

Nondaily preexposure prophylaxis for HIV prevention.

Anderson PL, GarcĂ­a-Lerma JG, Heneine W.

Curr Opin HIV AIDS. 2016 Jan;11(1):94-101. doi: 10.1097/COH.0000000000000213. Review.

41.

A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.

Keller MJ, Mesquita PM, Marzinke MA, Teller R, Espinoza L, Atrio JM, Lo Y, Frank B, Srinivasan S, Fredricks DN, Rabe L, Anderson PL, Hendrix CW, Kiser PF, Herold BC.

AIDS. 2016 Mar 13;30(5):743-51. doi: 10.1097/QAD.0000000000000979.

42.

Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.

Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Liegler T, Rawlings MK, Trainor N, Blue RW, Estrada Y, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA.

JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683.

43.

Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.

Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ.

Antimicrob Agents Chemother. 2015 Dec;59(12):7671-9. doi: 10.1128/AAC.01693-15. Epub 2015 Sep 28.

44.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.

45.

Evaluating changes in judgmental biases as mechanisms of cognitive-behavioral therapy for social anxiety disorder.

Calamaras MR, Tully EC, Tone EB, Price M, Anderson PL.

Behav Res Ther. 2015 Aug;71:139-49. doi: 10.1016/j.brat.2015.06.006. Epub 2015 Jun 16.

46.

Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.

Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W.

J Infect Dis. 2015 Dec 15;212(12):1988-95. doi: 10.1093/infdis/jiv334. Epub 2015 Jun 12.

47.

Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.

Meditz AL, Palmer C, Predhomme J, Searls K, Kerr B, Seifert S, Caraway P, Gardner EM, MaWhinney S, Anderson PL.

AIDS Res Hum Retroviruses. 2015 Oct;31(10):1015-22. doi: 10.1089/AID.2014.0301. Epub 2015 Jun 10.

48.

Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting.

Bjornstad P, Anderson PL, Maahs DM.

Acta Diabetol. 2016 Apr;53(2):331-3. doi: 10.1007/s00592-015-0764-6. Epub 2015 May 12. No abstract available.

49.

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Mulligan K, Glidden DV, Anderson PL, Liu A, McMahan V, Gonzales P, Ramirez-Cardich ME, Namwongprom S, Chodacki P, de Mendonca LM, Wang F, Lama JR, Chariyalertsak S, Guanira JV, Buchbinder S, Bekker LG, Schechter M, Veloso VG, Grant RM; Preexposure Prophylaxis Initiative Study Team.

Clin Infect Dis. 2015 Aug 15;61(4):572-80. doi: 10.1093/cid/civ324. Epub 2015 Apr 23.

50.

Strong Correlation Between Concentrations of Tenofovir (TFV) Emtricitabine (FTC) in Hair and TFV Diphosphate and FTC Triphosphate in Dried Blood Spots in the iPrEx Open Label Extension: Implications for Pre-exposure Prophylaxis Adherence Monitoring.

Gandhi M, Glidden DV, Liu A, Anderson PL, Horng H, Defechereux P, Guanira JV, Grinsztejn B, Chariyalertsak S, Bekker LG, Grant RM; iPrEx Study Team.

J Infect Dis. 2015 Nov 1;212(9):1402-6. doi: 10.1093/infdis/jiv239. Epub 2015 Apr 20.

Supplemental Content

Loading ...
Support Center